Neurodiagnostics Market
Description
Size, Share & Trends Analysis Report By Technology (Neuroimaging Technologies (Computed Tomography, Magnetic Resonance Imaging)), By End Use, By Region, And Segment Forecasts, 2026 - 2033
Neurodiagnostics Market Summary
The global neurodiagnostics market size was estimated at USD 19.01 billion in 2025 and is projected to reach USD 36.57 billion by 2033, growing at a CAGR of 8.52% from 2026 to 2033. This growth is primarily driven by the increasing prevalence of neurological disorders such as epilepsy, Alzheimer’s disease, Parkinson’s disease, stroke, and depression, which are creating sustained demand for accurate and early diagnostic solutions.
In addition, the rising geriatric population is significantly contributing to market expansion, as elderly individuals are more susceptible to neurodegenerative and cerebrovascular diseases.
Technological advancements such as AI-integrated imaging, portable EEG devices, and high-resolution MRI and CT systems are improving diagnostic accuracy and workflow efficiency, further accelerating adoption across hospitals and diagnostic centers.
The advancements in neuroimaging technologies and the launch of new and innovative technologies by the key players in the market are further anticipated to drive market growth. For instance, in January 2025, Siemens Healthineers unveiled its latest diagnostic imaging innovations at the Asian Oceanian Congress of Radiology (AOCR) 2025 held in Chennai, strengthening its commitment to transforming healthcare through safe, accessible, flexible, and sustainable technologies that support improved patient care.
The showcase featured the Dry Cool technology-enabled, virtually helium-free 1.5T MAGNETOM Flow MRI, the Dual Source CT scanner SOMATOM Pro. Pulse, the locally manufactured Digital X-ray system MULTIX Impact E, and AI-powered ultrasound systems ACUSON Maple and ACUSON Sequoia. These solutions are designed to enhance diagnostic accuracy, improve workflow efficiency, and expand access to high-quality imaging, particularly across diverse healthcare settings.
Depression drives growth in the neurodiagnostic industry. The rising global burden of depressive disorders is increasing demand for objective brain-based evaluation tools such as MRI, PET, and EEG to better understand disease mechanisms, support research, and guide treatment selection. Depression is a significant mental health disorder worldwide and a leading cause of disability, creating sustained clinical and research demand for advanced neurological assessment technologies. Neuroimaging and neurophysiological techniques are used to study brain circuit changes, identify biomarkers, and support the development of personalized therapies, which directly expands the use of neurodiagnostic equipment and services.
Global Neurodiagnostics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neurodiagnostics market report based on technology, end use, and region:
Neurodiagnostics Market Summary
The global neurodiagnostics market size was estimated at USD 19.01 billion in 2025 and is projected to reach USD 36.57 billion by 2033, growing at a CAGR of 8.52% from 2026 to 2033. This growth is primarily driven by the increasing prevalence of neurological disorders such as epilepsy, Alzheimer’s disease, Parkinson’s disease, stroke, and depression, which are creating sustained demand for accurate and early diagnostic solutions.
In addition, the rising geriatric population is significantly contributing to market expansion, as elderly individuals are more susceptible to neurodegenerative and cerebrovascular diseases.
Technological advancements such as AI-integrated imaging, portable EEG devices, and high-resolution MRI and CT systems are improving diagnostic accuracy and workflow efficiency, further accelerating adoption across hospitals and diagnostic centers.
The advancements in neuroimaging technologies and the launch of new and innovative technologies by the key players in the market are further anticipated to drive market growth. For instance, in January 2025, Siemens Healthineers unveiled its latest diagnostic imaging innovations at the Asian Oceanian Congress of Radiology (AOCR) 2025 held in Chennai, strengthening its commitment to transforming healthcare through safe, accessible, flexible, and sustainable technologies that support improved patient care.
The showcase featured the Dry Cool technology-enabled, virtually helium-free 1.5T MAGNETOM Flow MRI, the Dual Source CT scanner SOMATOM Pro. Pulse, the locally manufactured Digital X-ray system MULTIX Impact E, and AI-powered ultrasound systems ACUSON Maple and ACUSON Sequoia. These solutions are designed to enhance diagnostic accuracy, improve workflow efficiency, and expand access to high-quality imaging, particularly across diverse healthcare settings.
Depression drives growth in the neurodiagnostic industry. The rising global burden of depressive disorders is increasing demand for objective brain-based evaluation tools such as MRI, PET, and EEG to better understand disease mechanisms, support research, and guide treatment selection. Depression is a significant mental health disorder worldwide and a leading cause of disability, creating sustained clinical and research demand for advanced neurological assessment technologies. Neuroimaging and neurophysiological techniques are used to study brain circuit changes, identify biomarkers, and support the development of personalized therapies, which directly expands the use of neurodiagnostic equipment and services.
Global Neurodiagnostics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neurodiagnostics market report based on technology, end use, and region:
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Neuroimaging Technologies
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging (PET, SPECT)
- Near infrared spectroscopic imaging (NIRS)
- Electro-encephalography (EEG)
- Magneto-encephalography (MEG)
- Voxel based morphometry (VBM)
- In Vitro Diagnostics
- Neuroinformatics
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals and Clinics
- Diagnostic Laboratories
- Imaging Centers
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Neurodiagnostics Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.1.1. Rising prevalence of neurological disorders
- 3.3.1.2. Technological advancements
- 3.3.1.3. Government and private sector funding
- 3.3.2. Market Restraints Analysis
- 3.3.2.1. High cost of equipment and procedures
- 3.3.2.2. Limited reimbursement in emerging economies
- 3.3.3. Market Opportunity Analysis
- 3.3.3.1. Emergence of portable and point-of-care neurodiagnostic devices
- 3.3.3.2. Rising adoption in emerging markets
- 3.3.4. Market Challenge Analysis
- 3.3.4.1. Data privacy and integration issues
- 3.4. Neurodiagnostics Market Analysis Tools
- 3.4.1. Porter’s Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- Chapter 4. Neurodiagnostics Market: Technology Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Neurodiagnostics Market: Technology Movement Analysis, USD Million, 2025 & 2033
- 4.3. Neuroimaging Technologies
- 4.3.1. Neuroimaging Technologies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2. Computed Tomography (CT)
- 4.3.2.1. Computed Tomography (CT) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3. Magnetic Resonance Imaging (MRI)
- 4.3.3.1. Magnetic Resonance Imaging (MRI) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.4. Nuclear Medicine Imaging (PET, SPECT)
- 4.3.4.1. Nuclear Medicine Imaging (PET, SPECT) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.5. Near infrared spectroscopic imaging (NIRS)
- 4.3.5.1. Near infrared spectroscopic imaging (NIRS) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.6. Electro-encephalography (EEG)
- 4.3.6.1. Electro-encephalography (EEG) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.7. Magneto-encephalography (MEG)
- 4.3.7.1. Magneto-encephalography (MEG) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.8. Voxel based morphometry (VBM)
- 4.3.8.1. Voxel based morphometry (VBM) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. In Vitro Diagnostics
- 4.4.1. In Vitro Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Neuroinformatics
- 4.5.1. Neuroinformatics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Neurodiagnostics Market: End Use Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Neurodiagnostics Market: End Use Movement Analysis, USD Million, 2025 & 2033
- 5.3. Hospitals and Clinics
- 5.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Diagnostic Laboratories
- 5.4.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Imaging Centers
- 5.5.1. Imaging Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Others
- 5.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Neurodiagnostics Market: Regional Estimates & Trend Analysis, by Technology and by End Use
- 6.1. Neurodiagnostics Market Share, By Region, 2025 & 2033, USD Million
- 6.2. North America
- 6.2.1. North America Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.2. U.S.
- 6.2.2.1. U.S. Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.3. Canada
- 6.2.3.1. Canada Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.4. Mexico
- 6.2.4.1. Mexico Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3. Europe
- 6.3.1. Europe Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.2. UK
- 6.3.2.1. UK Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.3. Germany
- 6.3.3.1. Germany Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.4. France
- 6.3.4.1. France Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.5. Italy
- 6.3.5.1. Italy Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.6. Spain
- 6.3.6.1. Spain Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.7. Denmark
- 6.3.7.1. Denmark Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.8. Sweden
- 6.3.8.1. Sweden Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.9. Norway
- 6.3.9.1. Norway Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Asia Pacific
- 6.4.1. Asia Pacific Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.2. China
- 6.4.2.1. China Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.3. Japan
- 6.4.3.1. Japan Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.4. India
- 6.4.4.1. India Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.5. South Korea
- 6.4.5.1. South Korea Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.6. Australia
- 6.4.6.1. Australia Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.7. Thailand
- 6.4.7.1. Thailand Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Latin America
- 6.5.1. Latin America Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.2. Brazil
- 6.5.2.1. Brazil Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.3. Argentina
- 6.5.3.1. Argentina Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Middle East and Africa
- 6.6.1. Middle East and Africa Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.2. Saudi Arabia
- 6.6.2.1. Saudi Arabia Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.3. UAE
- 6.6.3.1. UAE Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.4. South Africa
- 6.6.4.1. South Africa Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.5. Kuwait
- 6.6.5.1. Kuwait Neurodiagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis by Key Market Participants
- 7.2. Company Categorization
- 7.3. Company Share Analysis, 2025
- 7.4. Company Profiles
- 7.4.1. Canon Medical Systems Corporation
- 7.4.1.1. Participant’s Overview
- 7.4.1.2. Financial Performance
- 7.4.1.3. Product Benchmarking
- 7.4.1.4. Recent Developments/ Strategic Initiatives
- 7.4.2. Siemens Healthineers AG
- 7.4.2.1. Participant’s Overview
- 7.4.2.2. Financial Performance
- 7.4.2.3. Product Benchmarking
- 7.4.2.4. Recent Developments/ Strategic Initiatives
- 7.4.3. Koninklijke Philips N.V.
- 7.4.3.1. Participant’s Overview
- 7.4.3.2. Financial Performance
- 7.4.3.3. Product Benchmarking
- 7.4.3.4. Recent Developments/ Strategic Initiatives
- 7.4.4. Thermo Fisher Scientific, Inc.
- 7.4.4.1. Participant’s Overview
- 7.4.4.2. Financial Performance
- 7.4.4.3. Product Benchmarking
- 7.4.4.4. Recent Developments/ Strategic Initiatives
- 7.4.5. FUJIFILM Corporation
- 7.4.5.1. Participant’s Overview
- 7.4.5.2. Financial Performance
- 7.4.5.3. Product Benchmarking
- 7.4.5.4. Recent Developments/ Strategic Initiatives
- 7.4.6. Natus Medical Incorporated (ARCHIMED)
- 7.4.6.1. Participant’s Overview
- 7.4.6.2. Financial Performance
- 7.4.6.3. Product Benchmarking
- 7.4.6.4. Recent Developments/ Strategic Initiatives
- 7.4.7. Lifelines Neuro (SIDIS)
- 7.4.7.1. Participant’s Overview
- 7.4.7.2. Financial Performance
- 7.4.7.3. Product Benchmarking
- 7.4.7.4. Recent Developments/ Strategic Initiatives
- 7.4.8. Advanced Brain Monitoring, Inc.
- 7.4.8.1. Participant’s Overview
- 7.4.8.2. Financial Performance
- 7.4.8.3. Product Benchmarking
- 7.4.8.4. Recent Developments/ Strategic Initiatives
- 7.4.9. NIHON KOHDEN CORPORATION.
- 7.4.9.1. Participant’s Overview
- 7.4.9.2. Financial Performance
- 7.4.9.3. Product Benchmarking
- 7.4.9.4. Recent Developments/ Strategic Initiatives
- 7.4.10. F. Hoffmann-La Roche Ltd
- 7.4.10.1. Participant’s Overview
- 7.4.10.2. Financial Performance
- 7.4.10.3. Product Benchmarking
- 7.4.10.4. Recent Developments/ Strategic Initiatives
- 7.4.11. GE HealthCare.
- 7.4.11.1. Participant’s Overview
- 7.4.11.2. Financial Performance
- 7.4.11.3. Product Benchmarking
- 7.4.11.4. Recent Developments/ Strategic Initiatives
- 7.4.12. Mitsar Co. LTD.
- 7.4.12.1. Participant’s Overview
- 7.4.12.2. Financial Performance
- 7.4.12.3. Product Benchmarking
- 7.4.12.4. Recent Developments/ Strategic Initiatives
- 7.4.13. Deymed Diagnostic
- 7.4.13.1. Participant’s Overview
- 7.4.13.2. Financial Performance
- 7.4.13.3. Product Benchmarking
- 7.4.13.4. Recent Developments/ Strategic Initiatives
- 7.4.14. Neurosoft
- 7.4.14.1. Participant’s Overview
- 7.4.14.2. Financial Performance
- 7.4.14.3. Product Benchmarking
- 7.4.14.4. Recent Developments/ Strategic Initiatives
- 7.4.15. Cadwell Industries
- 7.4.15.1. Participant’s Overview
- 7.4.15.2. Financial Performance
- 7.4.15.3. Product Benchmarking
- 7.4.15.4. Recent Developments/ Strategic Initiatives
- 7.4.16. Compumedics Limited
- 7.4.16.1. Participant’s Overview
- 7.4.16.2. Financial Performance
- 7.4.16.3. Product Benchmarking
- 7.4.16.4. Recent Developments/ Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
